Lilly reports Phase 3 obesity results for retatrutide: what TRIUMPH-1 showed

What the three doses produced

The study randomized participants 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, all given once weekly.[1] Participants started at 2 mg and escalated in four-week steps to reach their assigned target dose.[1] The average starting body weight across the four groups was 112.7 kg (248.5 lbs), with an average BMI of 40.0, placing the enrolled population in the severe obesity range.[1]

At 80 weeks, average body weight change versus placebo was: 4 mg group, minus 19.0 percent (47.2 lbs); 9 mg group, minus 25.9 percent (64.4 lbs); 12 mg group, minus 28.3 percent (70.3 lbs). Placebo participants lost an average of 2.2 percent (5.5 lbs).[1] These are the treatment-estimand results, which include participants who stopped taking the drug.[1]

The share of 12 mg participants achieving large weight reductions: 62.5 percent lost 25 percent or more; 45.3 percent lost 30 percent or more; 27.2 percent lost 35 percent or more.[1] For comparison, 0.5 percent of placebo participants reached the 30 percent threshold.[1] The 4 mg dose, which required only a single escalation step from 2 mg, produced 15.3 percent with 30 percent or more weight loss.[1] This dose-tiering detail matters for clinical planning, as a simpler titration schedule may suit patients who cannot tolerate aggressive escalation.[1]

The 104-week extension: a different group

Lilly also reported results from a pre-specified extension period that continued to 104 weeks.[1] This extension enrolled 532 participants, specifically those with a baseline BMI of 35 or higher who completed the 80-week study and tolerated their assigned dose.[1] These are not the same 2,339 people, and the extension population was more severely obese at baseline (average 121.7 kg, BMI 42.8) and had already shown they could stay on treatment.[1]

In the extension, participants were re-escalated to their maximum tolerated dose of 9 mg or 12 mg.[1] At 104 weeks, the 12 mg group in this extension averaged 30.3 percent body weight loss (85.0 lbs).[1] Participants who had been on placebo during the main trial and switched to retatrutide for the extension averaged 19.2 percent loss at the same timepoint.[1] These results describe a selected subset and a longer treatment duration, not the full trial population.[1]

Adverse events: what appeared and what to watch

The most common adverse events were gastrointestinal, consistent with other incretin-based therapies: nausea (42.4 percent on 12 mg versus 14.8 percent on placebo), diarrhea (32.0 versus 13.5), constipation (26.1 versus 10.9), and vomiting (25.3 versus 4.8).[1] Discontinuation rates due to adverse events rose with dose: 4.1 percent (4 mg), 6.9 percent (9 mg), and 11.3 percent (12 mg), compared with 4.9 percent for placebo.[1]

One signal worth watching is dysesthesia, an abnormal skin sensation. Dysesthesia occurred in 12.5 percent of the 12 mg group and 12.3 percent of the 9 mg group, versus 0.9 percent on placebo.[1] Lilly reports that most cases were mild to moderate, most resolved during treatment, and most participants continued taking retatrutide.[1] Dysesthesia has not been a prominent signal in semaglutide or tirzepatide trials, making it a compound-specific finding to monitor in larger and longer data.[1]

Upper respiratory tract infections also appeared across groups: 14.2 percent (4 mg), 12.2 percent (9 mg), 13.1 percent (12 mg), versus 11.6 percent on placebo.[1] These rates are similar across all treatment arms and close to placebo, suggesting this is background rather than a drug effect.[1]

What makes retatrutide different from tirzepatide

Retatrutide activates three hormone receptors: GIP, GLP-1, and glucagon.[1] Approved drugs in the class act on one or two. Semaglutide targets GLP-1 alone. Tirzepatide adds GIP.[2] The third target in retatrutide, the glucagon receptor, is thought to increase energy expenditure rather than primarily reducing food intake, which makes the mechanism biologically distinct.[2]

However, comparing Phase 3 trial numbers across drugs is not the same as a head-to-head study. Tirzepatide's SURMOUNT-1 results were generated in a different population with different entry criteria, over a different duration, and prior to 2026 changes in how the GLP-1 market and background treatments look.[2] TRIUMPH-5, a direct comparison of retatrutide against tirzepatide in adults with obesity, is in Phase 3 and has not reported.[3] Until those results are published, any comparison between the two compounds' efficacy numbers is an approximation.[3]

What this Phase 3 result does and does not establish

TRIUMPH-1 establishes that retatrutide met its pre-specified endpoints in adults with obesity or overweight without diabetes, at a dose that requires up to five escalation steps over roughly 16 weeks.[1][2] These are the data a regulatory filing would include for that population.[1]

What it does not establish: how retatrutide performs in people with type 2 diabetes (TRIUMPH-2, pending), what happens to cardiovascular outcomes (TRIUMPH-3, NCT05882045, now completed enrollment), how it compares directly to tirzepatide (TRIUMPH-5, pending), or whether the 80-week weight loss is maintained after stopping the drug.[1][2][3] No head-to-head FDA approval exists; retatrutide remains investigational and is legally available only to participants in Lilly's clinical trials.[1]

The May 21, 2026 results are a Lilly investor press release, not a peer-reviewed publication. Full statistical tables and subgroup analyses will be presented at scientific conferences and eventually published in journals.[1] A press release carries different evidentiary weight than a full trial paper, particularly for adverse event breakdowns and secondary endpoints not yet detailed in public documents.[1]

Frequently asked questions

Sources and further reading

1. Lilly investor press release: TRIUMPH-1 topline results (May 21, 2026)
2. ClinicalTrials.gov NCT05929066: TRIUMPH-1
3. ClinicalTrials.gov NCT05882045: TRIUMPH-3 (cardiovascular outcomes)

Related reading

• Roche reports Phase 2 enicepatide results in adults with type 2 diabetes
• What research use only means in 2026